BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report released on Wednesday morning. The firm issued a sell rating on the medical technology company’s stock.

Separately, Benchmark restated a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Stock Down 4.3 %

Shares of NASDAQ BIOL opened at $0.01 on Wednesday. BIOLASE has a fifty-two week low of $0.02 and a fifty-two week high of $1.94. The firm’s 50-day simple moving average is $0.01 and its 200 day simple moving average is $0.04. The stock has a market cap of $300,663.00, a P/E ratio of 0.00 and a beta of 0.67.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.